<DOC>
	<DOCNO>NCT00413205</DOCNO>
	<brief_summary>This 2 arm study investigate efficacy , safety tolerability RAR Gamma versus placebo ex-smokers moderate severe emphysema treat optimal COPD therapy . Following optimization COPD therapy ( 6 week ) patient randomize receive either RAR Gamma ( 5mg ) placebo daily use 2:1 ratio ( active : placebo ) , addition standard therapy . Following double-blind treatment period , patient enter 4-week follow-up period . The anticipated time study period 1-2 year , target sample size 100-500 individual .</brief_summary>
	<brief_title>TESRA : ( Treatment Emphysema With Gamma-Selective Retinoid Agonist )</brief_title>
	<detailed_description />
	<mesh_term>Emphysema</mesh_term>
	<mesh_term>Pulmonary Emphysema</mesh_term>
	<criteria>patient &gt; 44 year age , &gt; 10 packyear smoke history ; woman childbearing potential ; exsmokers ( must stop smoke &gt; =12 month ) clinical diagnosis emphysema ; willing switch optimal COPD therapy . oral steroid &gt; 28 day prior enrollment ; &gt; 2 exacerbation pulmonary symptom require outpatient treatment , &gt; 1 exacerbation require hospitalization , within 12 month prior screen ; exposure synthetic oral retinoids past 12 month ; history allergy sensitivity retinoids .</criteria>
	<gender>All</gender>
	<minimum_age>44 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>